JSC Grindeks will closer cooperate with Latvian Institute of Organic Synthesis

JSC Grindeks will closer cooperate with Latvian Institute of Organic Synthesis

11/11/2010

Referring to the information, published at the news portal BNS, JSC Grindeks confirms that expansion of cooperation with the Latvian Institute of Organic Synthesis is being considered. With the aim to combine scientific work and the production of pharmaceuticals, JSC Grindeks would consider buying the Institute of Organic Synthesis, if such opportunity existed.

On Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Product portfolio of Grindeks consists of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, the USA. JSC Grindeks shares are listed in the Official List of “Nasdaq OMX Riga”.

Further information:

Ilze Kreicmane
Deputy Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083336, (+371) 26466681
Fax: (+371) 67083505
[email protected]

Related posts

The Union of employees of JSC Grindeks signs a Collective Labour Agreement for 2008

Today, on December 17 2007, the Chairman of the union of JSC Grindeks employees Gunārs Skubiņš and the Chairman of the board of JSC Grindeks Janis Romanovskis signed a collective labour agreement for 2008. The provisions of the agreement apply to all employees of JSC Grindeks and provide the conditions that ensure social security for […]
17/12/2008
nine months of 2016

On Grindeks financial results in the first nine months of 2016

Today, on 25 November, the JSC Grindeks submitted the non-audited consolidated financial statements for the first nine months of 2016 to “Nasdaq Riga”. Non-audited financial results indicate that the Group’s turnover in the first nine months of 2016 was 72.4 million euro and has increased by 8.9 million euro or 14% in comparison to the […]
25/11/2016
magnifiercrossmenu